Alzheimer’s Treatment Granted FDA Approval

The U.S. FDA has granted Novartis Pharmaceuticals Corporation marketing clearance for Exelon (rivastigmine tartrate) capsules, a cholinesterase inhibitor for the treatment of mild to moderate Alzheimer’s disease. Exelon therapy is proven effective in multiple phase III trials in the three key domains used to assess the disease — global functioning (including activities of daily living Read more about Alzheimer’s Treatment Granted FDA Approval[…]

skye pharma

Skyepharma Plans Joint Development With Novartis

SkyePharma PLC announced an agreement with Novartis Pharma AG to jointly develop a new product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The product will combine Novartis’ novel long-acting bronchodilator QAB149 with two SkyePharma technologies SkyeHaler(TM), a breath-activated multi-dose dry powder inhaler (MDDPI) device, to be marketed by Novartis as the Read more about Skyepharma Plans Joint Development With Novartis[…]


Discovery Services Agreement For Novartis And Transgenomic

Transgenomic Inc. has entered into several specific agreements with Novartis Pharmaceuticals Corp. to provide mutation discovery services in the context of translational research programs in oncology. The goal is to support biomarker discovery efforts in the context of clinical trials by identifying genetic mutations that correlate with patients’ response(s) to cancer therapeutics. Transgenomic has performed Read more about Discovery Services Agreement For Novartis And Transgenomic[…]


Chiron Licenses Acute Rejection Agent From Novartis

Chiron has acquired exclusive worldwide development and commercialization rights to aerosolized cyclosporine (AcsA), an agent with potential in lung transplant acute rejection from Novartis. Clinical studies have been conducted in about 100 lung transplant patients at the University of Pittsburgh. Terms of agreement were not disclosed. Chiron Corporation, headquartered in Emeryville, California, has a strategic Read more about Chiron Licenses Acute Rejection Agent From Novartis[…]

Purchase Dragon Pharma Labs Overseas

Cut Long 300

Injectable Anabolic Steroid
Base Ingredient: Drostanolone Enanthate, Testosterone Enanthate, Trenbolone Enanthate
Producer: Dragon Pharma LLC
Unit: 1 X 10 ml (300 mg/ml)

Enantat 250 - Cheap Price

Administration: Injection
Principal Component: Testosterone Enanthate
Manufacturer: Dragon Pharma LLC
Unit: 20 x 10 mL vial (250 mg/mL)
Price: 20 x $30.00


Synthetic Anabolic Steroidal Agent
Active Ingredient: Oxymetholone
Made by: Dragon Pharma Labs
Package: 1 X 100 pills (50 mg/tablet)


Selective Estrogen Receptor Modulator
Primary Constituent: Clomiphene Citrate
Manufacturer: Dragon Pharmaceuticals
Unit: 1 X 100 tabs (50 mg/pill)

Cypionat 250

Injectable Anabolic Steroid
Main Constituent: Testosterone Cypionate
Produced by: Dragon Pharma
Amount: 1 X 10 ml (250 mg/ml)

EQ 200 / Test E 200

Injectable Anabolic Steroid
Basal Component: Boldenone Undecylenate, Testosterone Enanthate
Producer: Dragon Pharma Labs
Unit: 1 X 10 mL vial (400 mg/mL)

Masteron 100 - Bulk Price

Administration: Injection
Primary Substance: Drostanolone Di-Propionate
Manufacturer: Dragon Pharma LLC
Unit: 10 x 10 mL vial (100 mg/mL)
Price: 10 x $49.00

Primobolan 100

Injectable Steroid for Muscle Growth
Basal Component: Methenolone Enanthate
Made by: Dragon Pharmaceuticals
10 mL Sterile Multi-dose Vial (100 mg/mL)

Sustanon 350 [10 Vials]

Injectable Steroid for Muscle Growth
Mix of:
- 42mg Testosterone Propionate
- 84mg Testosterone Isocaproate
- 84mg Testosterone PhenylPropionate
- 140mg Testosterone Decanoate
Producer: Dragon Pharma
10 Vials [10 mL per Vial (350 mg/ml)]
Price: 10 x $45.00 = $450.00 in Total


Basal Ingredient: Oxymetholone
Producer: Dragon Pharma LLC
Pack: 100 tablets (50 mg/pill)

Cut Long 300

Primary Substance: Drostanolone Enanthate, Testosterone Enanthate
Trenbolone Enanthate
Made by: Dragon Pharma Labs
Pack: 10 mL vial (300 mg/mL)

Propionat 100

Prime Ingredient: Testosterone Propionate
Branded by: Dragon Pharmaceutical
Amount: 10 mL vial (100 mg/mL)